The sodium‐glucose co‐transporter 2 inhibitor tofogliflozin suppresses atherosclerosis through glucose lowering in ApoE‐deficient mice with streptozotocin‐induced diabetes

• Main Authors: Masahiko Iwamoto (Author), Tetsuya Kubota (Author), Yoshitaka Sakurai (Author), Nobuhiro Wada (Author), Seiji Shioda (Author), Toshimasa Yamauchi (Author), Takashi Kadowaki (Author), Naoto Kubota (Author)
• Format: Book
• Published: Wiley, 2022-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Epidemiological and animal studies have revealed that sodium‐glucose cotransporter 2 (SGLT2) inhibitors suppress cardiovascular events in subjects with type 2 diabetes and atherosclerosis in animal models of diabetes. However, it still remains unclear if the anti‐atherosclerotic effect of S...